LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
BRAF
Chemotherapy
Child
First-line
MAPK
Pediatric low-grade glioma
Tovorafenib
pLGG
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
30 Jan 2024
30 Jan 2024
Historique:
received:
31
08
2023
accepted:
02
01
2024
medline:
31
1
2024
pubmed:
31
1
2024
entrez:
30
1
2024
Statut:
epublish
Résumé
Pediatric low-grade glioma (pLGG) is essentially a single pathway disease, with most tumors driven by genomic alterations affecting the mitogen-activated protein kinase/ERK (MAPK) pathway, predominantly KIAA1549::BRAF fusions and BRAF V600E mutations. This makes pLGG an ideal candidate for MAPK pathway-targeted treatments. The type I BRAF inhibitor, dabrafenib, in combination with the MEK inhibitor, trametinib, has been approved by the United States Food and Drug Administration for the systemic treatment of BRAF V600E-mutated pLGG. However, this combination is not approved for the treatment of patients with tumors harboring BRAF fusions as type I RAF inhibitors are ineffective in this setting and may paradoxically enhance tumor growth. The type II RAF inhibitor, tovorafenib (formerly DAY101, TAK-580, MLN2480), has shown promising activity and good tolerability in patients with BRAF-altered pLGG in the phase 2 FIREFLY-1 study, with an objective response rate (ORR) per Response Assessment in Neuro-Oncology high-grade glioma (RANO-HGG) criteria of 67%. Tumor response was independent of histologic subtype, BRAF alteration type (fusion vs. mutation), number of prior lines of therapy, and prior MAPK-pathway inhibitor use. LOGGIC/FIREFLY-2 is a two-arm, randomized, open-label, multicenter, global, phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy vs. current standard of care (SoC) chemotherapy in patients < 25 years of age with pLGG harboring an activating RAF alteration who require first-line systemic therapy. Patients are randomized 1:1 to either tovorafenib, administered once weekly at 420 mg/m The promising tovorafenib activity data, CNS-penetration properties, strong scientific rationale combined with the manageable tolerability and safety profile seen in patients with pLGG led to the SIOPe-BTG-LGG working group to nominate tovorafenib for comparison with SoC chemotherapy in this first-line phase 3 trial. The efficacy, safety, and functional response data generated from the trial may define a new SoC treatment for newly diagnosed pLGG. ClinicalTrials.gov: NCT05566795. Registered on October 4, 2022.
Sections du résumé
BACKGROUND
BACKGROUND
Pediatric low-grade glioma (pLGG) is essentially a single pathway disease, with most tumors driven by genomic alterations affecting the mitogen-activated protein kinase/ERK (MAPK) pathway, predominantly KIAA1549::BRAF fusions and BRAF V600E mutations. This makes pLGG an ideal candidate for MAPK pathway-targeted treatments. The type I BRAF inhibitor, dabrafenib, in combination with the MEK inhibitor, trametinib, has been approved by the United States Food and Drug Administration for the systemic treatment of BRAF V600E-mutated pLGG. However, this combination is not approved for the treatment of patients with tumors harboring BRAF fusions as type I RAF inhibitors are ineffective in this setting and may paradoxically enhance tumor growth. The type II RAF inhibitor, tovorafenib (formerly DAY101, TAK-580, MLN2480), has shown promising activity and good tolerability in patients with BRAF-altered pLGG in the phase 2 FIREFLY-1 study, with an objective response rate (ORR) per Response Assessment in Neuro-Oncology high-grade glioma (RANO-HGG) criteria of 67%. Tumor response was independent of histologic subtype, BRAF alteration type (fusion vs. mutation), number of prior lines of therapy, and prior MAPK-pathway inhibitor use.
METHODS
METHODS
LOGGIC/FIREFLY-2 is a two-arm, randomized, open-label, multicenter, global, phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy vs. current standard of care (SoC) chemotherapy in patients < 25 years of age with pLGG harboring an activating RAF alteration who require first-line systemic therapy. Patients are randomized 1:1 to either tovorafenib, administered once weekly at 420 mg/m
DISCUSSION
CONCLUSIONS
The promising tovorafenib activity data, CNS-penetration properties, strong scientific rationale combined with the manageable tolerability and safety profile seen in patients with pLGG led to the SIOPe-BTG-LGG working group to nominate tovorafenib for comparison with SoC chemotherapy in this first-line phase 3 trial. The efficacy, safety, and functional response data generated from the trial may define a new SoC treatment for newly diagnosed pLGG.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov: NCT05566795. Registered on October 4, 2022.
Identifiants
pubmed: 38291372
doi: 10.1186/s12885-024-11820-x
pii: 10.1186/s12885-024-11820-x
doi:
Banques de données
ClinicalTrials.gov
['NCT05566795']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
147Informations de copyright
© 2024. The Author(s).
Références
Ostrom QT, Price M, Ryan K, Edelson J, Neff C, Cioffi G, et al. CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018. Neuro Oncol. 2022;24(Suppl 3):iii1–38.
doi: 10.1093/neuonc/noac161
pubmed: 36066969
pmcid: 9447434
Gnekow AK, Falkenstein F, von Hornstein S, Zwiener I, Berkefeld S, Bison B, et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol. 2012;14(10):1265–84.
doi: 10.1093/neuonc/nos202
pubmed: 22942186
pmcid: 3452343
Gnekow AK, Kandels D, Tilburg CV, Azizi AA, Opocher E, Stokland T, et al. SIOP-E-BTG and GPOH guidelines for diagnosis and treatment of children and adolescents with low grade glioma. Klin Padiatr. 2019;231(3):107–35.
doi: 10.1055/a-1471-5897
pubmed: 31108561
Goebel AM, Gnekow AK, Kandels D, Witt O, Schmidt R, Hernaiz Driever P. Natural history of pediatric low-grade glioma disease - first multi-state model analysis. J Cancer. 2019;10(25):6314–26.
doi: 10.7150/jca.33463
pubmed: 31772664
pmcid: 6856735
Alemany M, Velasco R, Simo M, Bruna J. Late effects of cancer treatment: consequences for long-term brain cancer survivors. Neurooncol Pract. 2021;8(1):18–30.
pubmed: 33664966
Heitzer AM, Ashford JM, Hastings C, Liu APY, Wu S, Bass JK, et al. Neuropsychological outcomes of patients with low-grade glioma diagnosed during the first year of life. J Neurooncol. 2019;141(2):413–20.
doi: 10.1007/s11060-018-03048-0
pubmed: 30467811
Liu APY, Hastings C, Wu S, Bass JK, Heitzer AM, Ashford J, et al. Treatment burden and long-term health deficits of patients with low-grade gliomas or glioneuronal tumors diagnosed during the first year of life. Cancer. 2019;125(7):1163–75.
doi: 10.1002/cncr.31918
pubmed: 30620400
Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(21):2641–7.
doi: 10.1200/JCO.2011.36.6054
pubmed: 22665535
pmcid: 3413276
Gnekow AK, Walker DA, Kandels D, Picton S, Giorgio P, Grill J, et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (</=16 years) low grade glioma - A final report. Eur J Cancer. 2017;81:206–25.
doi: 10.1016/j.ejca.2017.04.019
pubmed: 28649001
pmcid: 5517338
Lassaletta A, Scheinemann K, Zelcer SM, Hukin J, Wilson BA, Jabado N, et al. Phase II weekly vinblastine for chemotherapy-naive children with progressive low-grade glioma: A Canadian Pediatric Brain Tumor Consortium study. J Clin Oncol. 2016;34(29):3537–43.
doi: 10.1200/JCO.2016.68.1585
pubmed: 27573663
Kandels D, Pietsch T, Bison B, Warmuth-Metz M, Thomale UW, Kortmann RD, et al. Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low-grade glioma patients-Report from the German SIOP-LGG 2004 cohort. Int J Cancer. 2020;147(12):3471–89.
doi: 10.1002/ijc.33170
pubmed: 32580249
Fisher MJ, Jones DTW, Li Y, Guo X, Sonawane PS, Waanders AJ, et al. Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). Acta Neuropathol. 2021;141(4):605–17.
doi: 10.1007/s00401-021-02276-5
pubmed: 33585982
Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45(8):927–32.
doi: 10.1038/ng.2682
pubmed: 23817572
pmcid: 3951336
Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673–7.
doi: 10.1158/0008-5472.CAN-08-2097
pubmed: 18974108
pmcid: 2577184
Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008;118(5):1739–49.
doi: 10.1172/JCI33656
pubmed: 18398503
pmcid: 2289793
Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell. 2020;37(4):569-583e565.
doi: 10.1016/j.ccell.2020.03.011
pubmed: 32289278
pmcid: 7169997
Sturm D, Pfister SM, Jones DTW. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J Clin Oncol. 2017;35(21):2370–7.
doi: 10.1200/JCO.2017.73.0242
pubmed: 28640698
Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45(6):602–12.
doi: 10.1038/ng.2611
pubmed: 23583981
pmcid: 3727232
Buhl JL, Selt F, Hielscher T, Guiho R, Ecker J, Sahm F, et al. The senescence-associated secretory phenotype mediates oncogene-induced senescence in pediatric pilocytic astrocytoma. Clin Cancer Res. 2019;25(6):1851–66.
doi: 10.1158/1078-0432.CCR-18-1965
pubmed: 30530705
Selt F, Sigaud R, Valinciute G, Sievers P, Zaman J, Alcon C, et al. BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. Neuro Oncol. 2023;25(4):735–47.
doi: 10.1093/neuonc/noac199
pubmed: 35977048
Bouffet E, Hansford J, Garré ML, Hara J, Plant-Fox A, Aerts I, et al. Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600–mutant pediatric low-grade glioma (pLGG). J Clin Oncol. 2022;40(Suppl 17):LBA2002–LBA2002.
doi: 10.1200/JCO.2022.40.17_suppl.LBA2002
Tafinlar (dabrafenib) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s022lbl.pdf . Accessed 4 June 2023.
Schreck KC, Grossman SA, Pratilas CA: BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors. Cancers (Basel). 2019;11(9).
Bouffet E. Trametinib therapy in pediatric patients with low-grade gliomas (LGG) with BRAF gene fusion; a disease-specific cohort in the first pediatric testing of trametinib. Neuro Oncol. 2018;20(Suppl 2): i114.
doi: 10.1093/neuonc/noy059.387
pmcid: 6012791
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019;20(7):1011–22.
doi: 10.1016/S1470-2045(19)30277-3
pubmed: 31151904
pmcid: 6628202
Selt F, van Tilburg CM, Bison B, Sievers P, Harting I, Ecker J, et al. Response to trametinib treatment in progressive pediatric low-grade glioma patients. J Neurooncol. 2020;149(3):499–510.
doi: 10.1007/s11060-020-03640-3
pubmed: 33026636
pmcid: 7609413
Rosenberg T, Yeo KK, Mauguen A, Alexandrescu S, Prabhu SP, Tsai JW, et al. Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. Neuro Oncol. 2022;24(11):1964–75.
doi: 10.1093/neuonc/noac096
pubmed: 35397478
pmcid: 9629451
Stege H, Haist M, Schultheis M, Fleischer MI, Mohr P, Meier F et al: Discontinuation of BRAF/MEK-directed targeted therapy after complete remission of metastatic melanoma-a retrospective multicenter ADOReg study. Cancers (Basel). 2021;13(10).
Klesse LJ, Jordan JT, Radtke HB, Rosser T, Schorry E, Ullrich N, et al. The use of MEK inhibitors in Neurofibromatosis type 1-associated tumors and management of toxicities. Oncologist. 2020;25(7):e1109–16.
doi: 10.1634/theoncologist.2020-0069
pubmed: 32272491
pmcid: 7356675
Lugowska I, Kosela-Paterczyk H, Kozak K, Rutkowski P. Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther. 2015;8:2251–9.
pubmed: 26347206
pmcid: 4556032
Olszanski AJ, Gonzalez R, Corrie P, Pavlick AC, Middleton M, Lorigan P et al: Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis. Ann Oncol. 2017;28.
Sun Y, Alberta JA, Pilarz C, Calligaris D, Chadwick EJ, Ramkissoon SH, et al. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 2017;19(6):774–85.
pubmed: 28082416
pmcid: 5464455
Kilburn L, Khuong-Quang D-A, Nysom K, Landi D, Ziegler D, Hernáiz Driever P et al: Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study. J Clin Oncol. 2023;41 Suppl 16:abstr 10004 and associated presentation.
Rasco DW, Medina T, Corrie P, Pavlick AC, Middleton MR, Lorigan P, et al. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2023;92(1):15–28.
doi: 10.1007/s00280-023-04544-5
pubmed: 37219686
pmcid: 10261210
Kilburn L, Khuong-Quang D-A, Nysom K, Landi D, Ziegler D, Hernáiz Driever P et al: Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study. Neuro Oncol. 2023;25 i57 and associated presentation.
van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12(6):583–93.
doi: 10.1016/S1470-2045(11)70057-2
pubmed: 21474379
Hardin EC, Schmid S, Sommerkamp A, Bodden C, Heipertz AE, Sievers P et al: LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. Neuro Oncol. 2023; noad078.
Sigaud R, Albert TK, Hess C, Hielscher T, Winkler N, Kocher D, et al. MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas. Nat Commun. 2023;14(1):4533.
doi: 10.1038/s41467-023-40235-8
pubmed: 37500667
pmcid: 10374577
Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993;11(5):850–6.
doi: 10.1200/JCO.1993.11.5.850
pubmed: 8487049
Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response assessment in neuro-oncology clinical trials. J Clin Oncol. 2017;35(21):2439–49.
doi: 10.1200/JCO.2017.72.7511
pubmed: 28640707
pmcid: 5516482
Fangusaro J, Witt O, Hernaiz Driever P, Bag AK, de Blank P, Kadom N, et al. Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020;21(6):e305–16.
doi: 10.1016/S1470-2045(20)30064-4
pubmed: 32502457
Day One Bio March 6, 2023 press release. https://ir.dayonebio.com/news-releases/news-release-details/day-one-reports-fourth-quarter-and-full-year-2022-financial . Accessed 14 December 2023.
DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2). https://clinicaltrials.gov/ct2/show/NCT05566795 . Accessed 4 June 2023.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–51.
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Vassal G, de Rojas T, Pearson ADJ. Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents. Lancet Child Adolesc Health. 2023;7(3):214–22.
doi: 10.1016/S2352-4642(22)00344-3
pubmed: 36682367
Dabrafenib With Trametinib for Pediatric Low-Grade Glioma With BRAF V600E Mutation. https://ascopost.com/issues/april-25-2023/dabrafenib-with-trametinib-for-pediatric-low-grade-glioma-with-braf-v600e-mutation/ . Accessed 16 August 2023.
Kilburn L, Landi D, Leary S, Ziegler D, Baxter P, Franson A, et al. FIREFLY-1 (PNOC026): Phase 2 study of pan-Raf inhibitor tovorafenib in pediatric and young adult patients with Raf-altered recurrent or progressive low-grade glioma or advanced solid tumors. Neuro Oncol. 2022;24:89.
doi: 10.1093/neuonc/noac209.333